Microbot Medical announced today that it began the U.S. commercial launch of its Liberty endovascular surgical robot.

Microbot Medical Inc. (NASDAQ:MBOT) stock rose 5.8% Wednesday after the company announced the commercial availability of its LIBERTY® Endovascular Robotic System in the United States. The LIBERTY® ...

Microbot Medical Inc. announces key milestones, including FDA 510(k) submission, in preparation for LIBERTY's commercial launch in 2025. Microbot Medical Inc. announced the successful completion of ...

Company Completes the Required Infrastructure to Support the Introduction of LIBERTY® to the U.S. Market with the Hiring of the Core Commercial ...

Microbot Medical ( ($MBOT) ) has issued an announcement. On November 5, 2025, Microbot Medical announced the limited commercial availability of ...

Microbot Medical (MBOT) concludes 2024 with the achievement of several key milestones, including the recent FDA 510(k) submission for FDA commercial approval of LIBERTY, which the company believes ...

HINGHAM, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributer of the innovative LIBERTY ® Endovascular Robotic System, today announced that it will ...

HINGHAM, Mass., June 09, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY Endovascular Robotic System, today announced the continued expansion of its ...